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Background: Schizophrenia is a severe psychiatric disease characterized by a high heritability and a complex
genetic architecture. Recent reports based on exome sequencing analyses have highlighted a significant increase of
potentially deleterious de novo mutations in different genes in individuals with schizophrenia.
Findings: This report presents the mutation screening results of four candidate genes for which such de novo
mutations were previously reported (LRP1, KPNA1, ALS2CL and ZNF480). We have not identified any excess of rare
variants in the additional SCZ cases we have screened.
Conclusions: This supports the notion that de novo mutations in these four genes are extremely rare in
schizophrenia and further highlights the high degree of genetic heterogeneity of this disease.
Keywords: Schizophrenia, De novo mutation, LRP1, ALS2CL, KPNA1, ZNF480Schizophrenia (SCZ) is a neurodevelopmental psychia-
tric disorder that is characterized by severely impaired
cognitive processes causing hallucinations, delusions and
altered emotional reactivity that disturb social behavior.
This disorder is highly prevalent and according to the
National Institute of Mental Health affects 1.1% of the
U.S. adult population. The genetic factors predisposing
to SCZ have not been fully elucidated but twin, adoptee
and family studies jointly suggest that genetics is impor-
tant with a heritability estimated to be up to 80% [1,2].
Multiple approaches have been used to identify common
and rare SCZ-predisposing variants using candidate gene
and whole genome-scale studies [3,4]. However neither
large-scale sequencing projects, looking for rare pene-
trant variants, nor genome wide association studies,
looking for common variants, have accounted for a* Correspondence: guy.rouleau@umontreal.ca
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reproduction in any medium, provided the orsignificant fraction of the heritability of SCZ. In light of
this limited success, it was hypothesized that deleterious
de novo mutations in any of several different genes could
explain the high global incidence of SCZ despite a
reduced reproductive fitness. Our group first reported
the presence of a significant excess of potentially dele-
terious de novo mutations in 401 synaptic genes using
Sanger sequencing in a cohort of SCZ and autism
patients [5]. We have later confirmed an excess of
exonic de novo mutations and more particularly of non-
sense variants in 15 SCZ trios (probands and parents)
using exome sequencing. Interestingly, 4:11 ratio of non-
sense to missense mutations is significantly higher than
the expected 1:20 ratio (P = 0.005467), and according to
the Human Gene Mutation Database, the expected ratio
of nonsense to missense among all mutations reported
to cause Mendelian diseases is 1:4 which in line with
what we found (P > 0.05, not significant). This identified
four candidate genes (LRP1, KPNA1, ALS2CL and
ZNF480) possibly involved in SCZ [6]. The presenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genes in additional 475 SCZ cases and 189 controls.
Probands were individually interviewed and their diag-
nosis was based on the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition. Exclusion criteria
included patients with psychotic symptoms caused by al-
cohol, drug abuse or other clinical diagnosis. All samples
were collected through informed consent following the
approval of their respective institutional ethics review
committees. An initial cohort of 189 SCZ patients of
European Caucasian ancestry was used in this study. An
additional cohort of 285 SCZ subjects, also of European
Caucasian ancestry, was used for the screening of
ALS2CL and ZNF480 genes. All coding regions and
splice site junctions of LRP1, KPNA1, ALS2CL and
ZNF480 genes were amplified and then sequenced using
Sanger sequencing technology. Variant detection analysis
was done using Mutation Surveyor (v. 3.23, Softgenetics)
and rare exonic variants were confirmed by re-
amplification of the relevant fragment in both probands
and parents (when available) using forward and reverse
oligos.
The first gene, LRP1 (NM002332, 89 exons) encodes
for Homo Sapiens low density lipoprotein receptor-
related protein 1 and is located at 12q13-14. We identi-
fied four rare LRP1 variants (S278I, R379H, M1795I and
G3948D) absent from public databases (dbSNP [7], 1000
genome project [8] and Exome Variant Server (EVS) [9])
and two additional variants (G169D and A2160T) only
reported in EVS at a very low frequency (Table 1). Inter-
estingly, the missense G169D is predicted to affect pro-
tein function by SIFT (0.01) and Polyphen (2.337)
predicting softwares [10,11]. Unfortunately the parents’
DNAs were not available for an inheritance study. We
also identified eight other LRP1 variants that were previ-
ously deposited in EVS database and their minor-allele
frequencies ranged from 1 to 159 / 10 755 to 10 599
total alleles. Two of these, G3725E and R1993W, are
predicted to affect protein function despite minor-allele
frequencies of 12/ 10 746 and 25/ 10 733, respectively.
However, the fact that G3725E is transmitted by an un-
affected mother, suggests it is unlikely to play a major
role in SCZ. Unlike the original published findings, we
did not find any highly damaging variant (ie. nonsense
or insertion/deletion) in LRP1 gene. The KPNA1 gene
screening (NM002264; 14 exons), which encodes for
karyopherin alpha 1 protein and is located at 3q21, did
not lead to the identification of rare variants in our SCZ
cohort. The sequencing of ALS2CL (NM147129; 26
exons), encoding for ALS2 C-terminal like protein and
located at 3p21.31, revealed one nonsense mutation
(E65X) in one SCZ patient. Because of this ALS2CL vari-
ant, we opted to screen the full gene in 286 additional
SCZ patients and 189 control individuals. We observeda minor-allele frequency of 4/475 SCZ patients and of
1/189 controls for E65X. This variant has been lately
added to dbSNP (rs139496961) and EVS databases with
a minor allele-frequency of 20/10 738. The presence of
E65X in a control individual from our ethnically-
matched control cohort makes ALS2CL gene less likely
to predispose to SCZ. We also observed three additional
rare ALS2CL variants in our 189 initial cases (T268S,
T460M and P580S) but their pathogenicity is unlikely
since none of the prediction software predicted them
to be deleterious. Finally, the screening of ZNF480
(NM144684; 4 coding exons) a zinc finger protein which
is located at 19q13.41, led to the identification of two
nonsense variants in one SCZ patient and one control
individual (R276X and R500X, respectively). During our
gene screening process, five nonsense variations (R304X,
R360X, R416X, K434X and Q528X) were deposited in
the EVS database by other groups with frequencies ran-
ging from 1/10 755 to 2/10 756. Although we cannot
rule out that schizophrenic or borderline personalities
can be found in public databases such as EVS, the fact
that five additional nonsense variations were found in the
C-terminal region of this gene is not in favor of a deleteri-
ous effect of a de novo nonsense mutation in this region.
For this reason we did not further investigate this gene
in additional SCZ cases and control individuals and
concluded that ZNF480 was a poor candidate for SCZ.
While the results of this mutation screening effort did
not lead to the identification of additional potentially
deleterious de novo mutations in LRP1, KPNA1, ALS2CL
and ZNF480 in a larger cohort of SCZ patients, it was a
necessary first step to assess their possible contribution
to disease. One limitation of this study is that we have
focused only on the coding regions. This does not ex-
clude the involvement of disease predisposing variants
in non-coding regions, which could affect allelic expres-
sion or splicing. Given the known heterogeneity of SCZ
and the frequencies of variants reported thus far, the
contribution of these particular genes may only emerge
after the progressive sequencing of coding and non-
coding regions of these genes in much larger cohorts of
SCZ cases and control individuals. It’s likely that an add-
itional mechanism (like the polygenic mode) is involved
in the genetics of sporadic SCZ. However, we still believe
that deleterious de novo mutations play an important
role in a proportion of SCZ patients as demonstrated by
our group and others [14-16]. It is well known that SCZ
is genetically heterogeneous and hundreds and probably
thousands of genes are involved. Therefore, to date, very
few cases with de novo mutation have been reported to be
associated with the same genes. Addressing the complete
genetic picture of a polygenic disease such as SCZ is still a
major challenge and will require further independent repli-
cation studies to clarify the role of these genes.
Table 1 Mutations identified in LRP1, ALS2CL, ZNF480 and KPNA1 and occurrence in SCZ and CTR cohorts











LRP1 chr12:57,579,450 Y2200Xc NS de novo
LRP1 chr12:57,538,812 c.506G > A G169D MS - A = 2 / G = 10756 - N/A - 0.01 2.337 1/189 -
LRP1 chr12:57,539,265 c.833G > T S278I MS - - - T (mother) −2.47064 0.08 1.73 1/189 -
LRP1 chr12:57,548,392 c.1135G > A R379H MS - - - N/A −2.23136 0.07 1.571 1/189 -
LRP1 chr12:57,574,263 c.5386 + 1G > A M1795I MS - - - T (mother) - 0.06 1.968 1/189 -
LRP1 chr12:57,577,915 c.5977C > T R1993W MS rs141826184 T = 25 / C = 10733 T = 1 / C = 1093 N/A - 0.05 0.037 2/189 -
LRP1 chr12:57,578,673 c.6238G > A D2080N MS rs34577247 A = 159 / G = 10599 A = 26 / G = 2162 N/A - 0.45 0.375 >5 -
LRP1 chr12:57,579,328 c.6478G > A A2160T MS - A = 1 / G = 10495 - N/A - 0.60 1.147 1/189 -
LRP1 chr12:57,587,040 c.7637G > A G2546S MS rs113379328 A = 24 / G = 10734 - N/A - 0.13 0.836 >5 -
LRP1 chr12:57,587,717 c.7840G > A R2613Q MS rs150340911 A = 12 / G = 10746 - N/A - 0.36 0.898 2/189 -
LRP1 chr12:57,588,275 c.8057G > A R2686H MS rs148104493 A = 1 / G = 10755 - N/A - 0.12 0.999 1/189 -
LRP1 chr12:57,589,784 c.8699A > C Q2900P MS rs7397167 A = 123 / C = 10635 A = 14 / C = 2174 N/A - 0.53 - >5 -
LRP1 chr12:57,590,916 c.9044G > A G3015S MS rs145303173 A = 6 / G = 10752 - N/A - 0.76 0.357 2/189 -
LRP1 chr12:57,598,513 c.11175G > A G3725E MS rs151301245 A = 12 / G = 10746 - T (mother) - 0.03 1.583 1/189 -
LRP1 chr12:57,600,508 c.11843G > A G3948D MS - - - N/A - 0.50 1.357 1/189 -
ALS2CL chr3:46,717,166 R733Xc NS de novo
ALS2CL chr3:46,717,175 c.2188C > T G730S MS rs142971127 T = 80 / C = 10678 T = 12 / C = 2176 N/A - 0.40 1.483 7/475 1/189
ALS2CL chr3:46,718,458 c.1812G > T P605T MS - - - N/A −1.70789 0.42 1.761 0/475 1/189
ALS2CL chr3:46,718,477 c.1793C > T R598H MS - - - N/A −2.73328 0.01 1.686 0/475 1/189
ALS2CL chr3:46,719,769 c.1737G > A P580S MS - - - T (mother) - 0.62 1.615 1/475 0/189
ALS2CL chr3:46,719,861 c.1645T > C N549S MS rs140347863 C = 9 / T = 10749 - T (father). N/A. T (mother).
N/A
- 0.35 1.851 3/475 1/189
ALS2CL chr3:46,722,792 c.1380G > A T460M MS - A = 1 / G = 10757 - T (father) −2.00878 0.11 0.374 1/475 0/189
ALS2CL chr3:46,725,290 c.894G > A A298V MS rs141781567 A = 15 / G = 10757 - N/A −1.6125 0.14 1.366 2/475 0/189
ALS2CL chr3:46,725,522 c.802T > A T268S MS - - - T (mother) −1.48254 0.33 1.406 1/475 0/189
ALS2CL chr3:46,728,477 c.530A > G I176T MS rs145807890 G = 8 / A = 10746 - N/A −1.28647 0.39 1.351 0/475 1/189
ALS2CL chr3:46,729,700 c.190C > A E65X NS rs139496961 A = 20 / C = 10738 - N/A. T (father). N/A. N/A - - - 4/475 1/189
















Table 1 Mutations identified in LRP1, ALS2CL, ZNF480 and KPNA1 and occurrence in SCZ and CTR cohorts (Continued)
ZNF480 chr19:52,826,001 R500Xc NS de novo
ZNF480 chr19:52,825,329 c.826C > T R276X NS - - - N/A - - - 1/475 0/189
ZNF480 chr19:52,825,495 c.992C > A A331E MS - - - N/A - 0.95 0.838 0/475 1/189
ZNF480 chr19:52,826,001 c.1498C > T R500X NS - - - N/A - - - 0/475 1/189
KPNA1 chr3:122,146,472 E448Xc NS de novo
KPNA1 chr3:122,186,188 c.218C > T S73N MS rs4678193 T = 79 / C = 10677 T = 11 / C = 2177 N/A −2.16746 0.45 0.174 >5 -
a according to build Hg19; b variant position according to Mutalyzer 2.0.beta-20 [12] and to Genbank accession number NM_002332.2 for LRP1, NM_147129.3 for ALS2CL, NM_144684.2 for ZNF480 and NM_002264.3 for
KPNA1; c MS: missense and NS: nonsense; d nonsense mutations previously identified by exome sequencing [6]; e rs number as obtained in dbSNP database [7]; f observed allele counts according to Exome Variant
Server in all populations [9]; g observed allele counts according to 1000 genomes in all populations [8]; h inheritance study when parents available; i according to Panther, sub-PSEC score is the probability that a given
coding variant will cause a deleterious functional change when less than −3 [13]; j according to Sift scores (from 0 to 1), the amino acid substitution is predicted to be damaging if the score is < = 0.05 and tolerated if
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ExonPrimer: http://ihg.gsf.de/ihg/ExonPrimer.html.
Primer3 Plus interface: http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi.
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